IDH1/2

Gail Roboz | ASH 2018 | Key highlights of IDH inhibitors at ASH 2018

L:

Gail Roboz from the Weill Cornell Medicine, New York, US discusses of the use and advancement of IDH inhibitors in patients with IDH1 and IDH2 mutated acute myeloid leukemia (AML) at the 60th American Society Hematology Annual Meeting

Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF
Was this article informative? Thank you for your feedback!
100% of people found this article informative